- Home
- KALV vs ITIC Comparison
KALV vs ITIC Comparison
Compare KALV & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- ITIC
- Stock Information
- Founded
- KALV N/A
- ITIC 1972
- Country
- KALV United States
- ITIC United States
- Employees
- KALV N/A
- ITIC N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- ITIC Specialty Insurers
- Sector
- KALV Health Care
- ITIC Finance
- Exchange
- KALV Nasdaq
- ITIC Nasdaq
- Market Cap
- KALV 362.2M
- ITIC 404.7M
- IPO Year
- KALV N/A
- ITIC N/A
- Fundamental
- Price
- KALV $8.75
- ITIC $230.54
- Analyst Decision
- KALV Strong Buy
- ITIC
- Analyst Count
- KALV 7
- ITIC 0
- Target Price
- KALV $27.00
- ITIC N/A
- AVG Volume (30 Days)
- KALV 319.9K
- ITIC 12.7K
- Earning Date
- KALV 03-10-2025
- ITIC 02-11-2025
- Dividend Yield
- KALV N/A
- ITIC 6.85%
- EPS Growth
- KALV N/A
- ITIC 22.45
- EPS
- KALV N/A
- ITIC 15.10
- Revenue
- KALV N/A
- ITIC $241,018,000.00
- Revenue This Year
- KALV N/A
- ITIC N/A
- Revenue Next Year
- KALV N/A
- ITIC N/A
- P/E Ratio
- KALV N/A
- ITIC $15.10
- Revenue Growth
- KALV N/A
- ITIC 1.93
- 52 Week Low
- KALV $7.30
- ITIC $146.41
- 52 Week High
- KALV $16.88
- ITIC $290.40
- Technical
- Relative Strength Index (RSI)
- KALV 51.87
- ITIC 42.09
- Support Level
- KALV $7.30
- ITIC $225.24
- Resistance Level
- KALV $9.16
- ITIC $231.29
- Average True Range (ATR)
- KALV 0.41
- ITIC 5.99
- MACD
- KALV 0.07
- ITIC 0.79
- Stochastic Oscillator
- KALV 78.17
- ITIC 65.50
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About ITIC Investors Title Company
Investors Title Co operates primarily in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment primarily issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.